Skip to main content
HIKAL · Health Care · 2026-08-07

Hikal Ltd

3.7WatchWeak -0.2Stage 2 · wk 2In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹227.1
+2.58% today
₹2,801 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Visit company website →
Earnings Growth (YoY)
+68.3%
Revenue +37.3%
Dividend Yield
0.46%
P/B 2.2
vs 52W High
-30.8%
₹147.1 lo₹328.5 hi
30.8% below 52W high — far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
8.3%
200 DMA: ₹209.7 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
1.19x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 flat · -0.2% vs MA50 +4.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #78 of 79 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #52 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-12 → 2026-08-07
S4 21w
S2 37w
S4 46w
2023-05-122026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 4w → S1 8w → S4 21w → S1 6w → S2 3w → S1 1w → S4 7w → S1 3w → S2 37w → S3 8w → S2 11w → S3 3w → S4 46w → S1 10w → S2 1w current
Total tracked: 169 weeks across 15 stage runs.
1M
-2.8%
3M
+7.8%
6M
+21.9%
YTD
-2.8%
1Y
-29.7%
Scan Membership
Prop Scan
Latest: 2026-08-07
Breakout Watch
Latest: 2026-07-29
6 appearances in last 60 days. First seen: 2024-02-12.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 2 · Vol x
2026-08-06S2
Wk 2 · Vol x
2026-08-05S2
Wk 2 · Vol x
2026-08-04S2
Wk 1 · Vol x
2026-08-03S2
Wk 1 · Vol x
2026-07-31S2
Wk 1 · Vol x
2026-07-30S2
Wk 1 · Vol x
2026-07-29S21→2
Wk 1 · Vol x
2026-07-28S1
Wk 10 · Vol x
2026-07-27S1
Wk 9 · Vol x
2026-07-24S1
Wk 9 · Vol x
2026-07-23S1
Wk 9 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹213.1
200 DMA
₹209.7
52W High
₹328.5
52W Low
₹147.1
5D Low
₹221.4
Resistance levels (recent highs)
20d High
₹245.7
60d High
₹245.7
120d High
₹245.7
250d High
₹316
Next resistance
+8.2%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.